Posted 6 months ago

Dr. Kalmadi and The Growing Role of Immunotherapy in Targeting NSCLC Featured in Targeted Oncology

During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.

Sujith R. Kalmadi, MD

Dr. Kalmadi joined Ironwood Cancer and Research Centers in 2008 and serves as Chief Medical Officer. After finishing his medical schooling in India, Dr. Sujith Kalmadi completed his residency training and fellowship at the Cleveland Clinic in Cleveland, Ohio.

He then served as academic clinical faculty at the Cleveland Clinic School of Medicine (Lerner School) in Cleveland, Ohio, and subsequently at Baylor College of Medicine in Houston, Texas. During his tenure at these prestigious institutions, he pioneered several novel clinical research trials which have been lauded at national scientific meetings and published in peer reviewed journals.

Dr. Kalmadi is actively involved in the education of medical students and residents from Creighton University School of Medicine and Midwestern University and serves as a Clinical Assistant Professor in Hematology and Medical Oncology at both institutions. He has been selected multiple years by his professional peers as a Top Doc in PHOENIX Magazine.

His areas of clinical and research interests include several solid tumors, gastrointestinal malignancies, and hematological disorders. He has been the principal investigator in several innovative clinical trials across the years, which has led to FDA approval of several lifesaving cancer therapeutics.

He currently resides in Chandler with his wife and three children and enjoys tennis, chess, and racquetball during his spare time. He is board-certified in Internal Medicine, Hematology, and Medical Oncology.